- Home
- ICCM vs IXHL Comparison
ICCM vs IXHL Comparison
Compare ICCM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ICCM | IXHL |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 97.6M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ICCM | IXHL |
|---|---|---|
| Price | $0.63 | $4.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 150.4K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.11 |
| 52 Week High | $1.53 | $5.17 |
Technical Indicators
Market Signals| Indicator | ICCM | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 85.43 |
| Support Level | $0.59 | $0.31 |
| Resistance Level | $0.62 | $5.17 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | 0.01 | 0.36 |
| Stochastic Oscillator | 45.76 | 81.26 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.